To define, describe, and forecast the global preimplantation genetic testing market by technology, product & service, procedure type, application, end user, and region
“Preimplantation genetic testing market projected to grow at a CAGR of 10.0%”
The global preimplantation genetic testing market is expected to reach USD 541.8 million by 2022 from USD 336.4million in 2017, at a CAGR of 10.0%.
Growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are some of the key factors driving the growth of this market. However, the high procedural cost associated with preimplantation genetic testing and unsupportive government regulations are the factors restraining the growth of this market
“Next-generation Sequencing is expected to grow at the highest CAGR during 2017 to 2022”
By technology, the preimplantation genetic testing market covers next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single-nucleotide polymorphism (SNP). The NGS segment is expected to grow at the highest CAGR during 2017 to 2022, owing to benefits like reduced cost, better ability to detect an embryo with differing results (mosaicism), enhanced detection of structural abnormalities such as chromosomes with missing or duplicate segments, and reduction in human errors due to increased automation.
*Top 25 Companies Analysed for This Study are - Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc.
(U.S.), Agilent Technologies, Inc. (U.S.), Perkinelmer, Inc. (U.S.), Coopersurgical, Inc.
(U.S.), ABBott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), Scigene (U.S.), Beijing Genomics Institute (China), Good Start Genetics (U.S.), Invicta Genetics (Poland), Combimatrix Corporation (U.S.), Genea Limited (Australia), Progenesis (U.S.), Arrayit Corporation (U.S.), Macrogen, Inc.
(South Korea), Elucigene Diagnostics (U.K.), Reproductive Health Science Ltd. (Australia), Singlera Genomics, Inc.
(U.S.), Igenomix (Spain), Source Bioscience (U.K.), Pacgenomics (U.S.)
- Preimplantation Genetic Diagnosis and Screening Product Manufacturing Companies
- Preimplantation Genetic Diagnosis and Screening Service Providers
- Fertility Clinics and Maternity Centers
- Clinical Research Organizations (CROs)
- Academic Institutes and Research Institutes
- Medical Reimbursement and Insurance Providers
- Independent and Government Regulatory Bodies
Key point from table of content
7 Preimplantation Genetic Diagnosis and Screening Market, By Procedure Type
7.2 Preimplantation Genetic Screening
8 Preimplantation Genetic Diagnosis and Screening Market, By Technology
8.2 Next-Generation Sequencing
8.3 Polymerase Chain Reaction
9 Preimplantation Genetic Diagnosis and Screening Market, By Product and Service
9.2 Reagents and Consumables
10 Preimplantation Genetic Diagnosis and Screening Market, By Application
10.3 Structural Chromosomal Abnormalities
Browse Here for full Report with TOC: www.reportsnreports.com/reports/11…-st-to-2022.html